National Influenza Vaccine Summit
Scottsdale, Arizona – 17 May 2010

Tosh Butt
Executive Director, Influenza Franchise

©2010 The GlaxoSmithKline Group of Companies.
All Rights Reserved.

A Broad Portfolio Offering to Serve the Healthcare and Public Health Communities

Prevention - Immunization

Protection – Antiviral Prophylaxis & Virucidal Respirator

Treatment – Antiviral Treatment

Strong Research Pipeline to Complement our Current Portfolio
GSK Influenza Vaccine Products

- Approved for adults 18 years of age and older
- Available in a 5 mL multi-dose vial containing 10 doses (0.5 mL each)
- Contains Thimerosal as a preservative. Each 0.5 mL dose contains 25 micrograms of mercury
- Manufactured in Quebec, Canada

- Approved for use in persons 3 years of age and older
- Available in a 0.5 mL latex-free single-dose pre-filled syringe
- Thimerosal-free
- Manufactured in Dresden, Germany

Expanded Age Indication for Fluarix

- FLUARIX has been available in the US since 2005 for adults 18 years of age and older.

- In 2009, FDA expanded the age indication for FLUARIX for use in children 3 years of age and older

- FLUARIX is currently distributed in 80 countries worldwide
Vaccine Delivery Projections and Timing

- GSK estimates that up to 36 million doses total (Fluarix and FluLaval) will be supplied to the US
- GSK anticipates:
  - Beginning shipments in July
  - Shipping 50% of seasonal vaccine doses by the end of August
  - Completing shipments by the end of October
  - All estimates are dependent on regulatory approval

- These are early estimates provided for planning purposes and are not a commitment to dates and amounts of vaccine

Influenza Antiviral Prophylaxis and Treatment

- Relenza is recommended for:
  - Treatment of influenza in patients seven years of age and older who have been symptomatic for no more than 2 days
  - Prophylaxis of influenza in patients five years of age and older
- Relenza continues to be available in pharmacies for the Influenza season
- To date, no clinical cases of resistance to Relenza have been reported to any circulating influenza strains
GSK Pipeline: Next Generation Influenza Vaccine

- GSK is in the second year of a two year, global clinical trial (INFLUENCE 65) of over 43,000 participants, aged 65 years or older, to evaluate a new adjuvanted seasonal influenza vaccine

- The adjuvanted vaccine will be compared to currently marketed GSK seasonal vaccine in the prevention of laboratory confirmed influenza

- More than 200 million doses of GSK’s adjuvanted influenza vaccines have been distributed in more than 40 countries outside the US

Universal Mass Vaccination & Health Care Workers

**Universal Mass Vaccination (UMV):**
- UMV removes barriers to influenza immunization and signals the importance of preventing influenza across the entire population

**Continuing Challenges: Health Care Worker (HCW) Vaccination:**
- Although improving, HCW rates for influenza remain low. Interim results from January 2010 indicate that only 61.9% of HCW were vaccinated against seasonal influenza by January 2010

- The 2010 Section 317 Report to Congress specifically cites, “the resistance of healthcare personnel to getting vaccinated” as a barrier and challenge to adult immunization (p.37)
"It does not appear that the increased public discussion of the role of influenza vaccines has had a significant impact on the public’s behavior," said Katherine Harris, a senior economist at RAND.

Seventy-eight percent of those participating hospitals raised their vaccination rates...The 2009 Challenge asks hospitals to achieve a 65, 75, or 90 percent vaccination rate for JCR recognition, and it has been expanded to workers in ambulatory and long-term care facilities.

"To address the low flu vaccination rates among heart disease patients, Mended Hearts, Inc., launched "I Heart Flu Shots," an educational campaign that helps educate people living with heart disease about the importance of getting a seasonal flu shot. For more information about this campaign, go to www.IHeartFluShots.com."

- The American College of Cardiology (ACC)